A pivotal, Phase III trial of epacadostat in combination with pembrolizumab in patients with first-line non-small cell lung cancer (NSCLC)

Trial Profile

A pivotal, Phase III trial of epacadostat in combination with pembrolizumab in patients with first-line non-small cell lung cancer (NSCLC)

Planning
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 May 2017 According to an Incyte Corporation media release, this trial is expected to initiate in 2017.
    • 07 Apr 2017 New trial record
    • 31 Mar 2017 This trial will be conducted under the expanded collaboration for seven pivotal trials of Epacadostat and KEYTRUDA (pembrolizumab) between an Incyte Corporation and Merck, as reported in an Incyte Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top